CEGEDIM-RELATIONSHIP-MGT
Cegedim Relationship Management today announced the release of a pivotal thought leadership white paper, Multichannel: Insights for Measuring Effectiveness . which provides high-level, operational insights on the multichannel strategy. The white paper was developed under the leadership of Pierre Morgon, Chief Marketing Officer of Cegedim Group , capitalizing on the insights from his 25+ years’ experience in leading global operations and marketing in the Pharmaceutical industry. Along with results from a recent Cegedim Strategic Data promotion audit, the paper provides insights and techniques on how to transform current industry obstacles into exceptional value opportunities through a multichannel strategy.
The most innovative Life Sciences companies are now employing specialized multichannel strategies to generate engagement with their customers across a spectrum of marketing and communication channels. Since this strategy is new to the industry, companies must gain insights from solution providers and other companies – with experience implementing, deploying, and optimizing multichannel strategies – to learn best practices and achieve strong results.
Cegedim’s Latest Intelligence + Life Sciences Whitepaper Promotes Successful Multichannel Performance for Today’s Enterprises
Cegedim Relationship Management’s latest whitepaper outlines the fundamental elements of perfecting a multichannel strategy in the current Life Sciences landscape:
- Insight – an optimized strategy is built on in-depth understanding of processes and decision makers in patient, payer and physician communities.
- Channel & Message Selection – through deeper understanding, companies can decide on the channel combination, and message that will most effectively reach each customer.
- Channel & Message Orchestration – coherence among all channels and messages is vital to realizing the most ideal customer experience.
- Channel Optimization – companies must leverage the unique value of both personal and non-personal channels, such as the non-personal channels’ ability to engage customers otherwise unreachable through face- to-face interactions.
- Budget Balance – companies can achieve an optimal promotional budget by combining both high and low cost channels, such as face-to-face and remote detailing.
“The development of the multichannel engagement strategy for the life sciences industry is rapidly evolving, but its value opportunities have become too significant to ignore,” said Emiliano Gummati, Vice President Digital Engagement Solutions, Cegedim Relationship Management. “Through our recognized expertise, this whitepaper can help companies adopt and optimize the strategy to produce more meaningful customer engagement and better realization of their business goals.”
The Cegedim Strategic Data promotion audit found that non-personal channels produce near equal or better effects on physicians’ perception of added value; prescribing behavior; and the duration of visits from sales representatives – when compared to personal channels.
To access the full whitepaper, please click here .
To learn more about multichannel strategies for the Life Sciences industry, attend a free webinar on October 29, Multichannel - Insights for Measuring Effectiveness . Click here for more information and to register.
| About Cegedim Relationship Management: |
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group. To learn more, please visit: www.CegedimRM.com . Follow Cegedim Relationship Management on LinkedIn and Twitter . |
|||
| About Cegedim: |
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,100 people in more than 80 countries and generated revenue of €922 million in 2012. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com . Follow Cegedim on Twitter: @CegedimGroup . |
Contact:
Cegedim Relationship Management
Drew BUSTOS,
+1-(908)-443-2451
Global Communications
drew.bustos@cegedim.com
or
Cegedim
Aude
BALLEYDIER, +33-(0)1-49-09-68-81
Media Relations
aude.balleydier@cegedim.fr
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum